Core Insights - Lipella Pharmaceuticals has reported positive early tolerability results from its Phase 2a trial of LP-310 for Oral Lichen Planus (OLP), indicating that the treatment is well tolerated with no unpleasant taste [1][2][4] - LP-310 is a proprietary liposomal-tacrolimus formulation aimed at providing a more effective treatment for OLP, which currently has no FDA-approved pharmacotherapies [2][4] - The clinical trial is a multicenter, dose-ranging study evaluating the safety, tolerability, and efficacy of LP-310 at various doses, with five sites across the U.S. actively recruiting participants [3][4] Company Overview - Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating existing generic drugs for new applications, particularly targeting diseases with significant unmet medical needs [5] - The company completed its initial public offering in December 2022, indicating a commitment to advancing its drug development pipeline [5]

Core Insights - Aclarion has been added to the PRISM Emerging Medical Devices Index, highlighting its innovative position in the medtech sector with its AI-driven diagnostic solutions for chronic low back pain [1][3] - The U.S. medical devices market is projected to grow to nearly $315 billion by 2032, driven by increased R&D investments and innovations like Aclarion's NOCISCAN technology [1][2] Company Highlights - Aclarion's NOCISCAN technology is the first noninvasive diagnostic tool for identifying painful discs in patients with chronic low back pain, improving surgical outcomes [3][4] - The company addresses a significant healthcare expenditure, with the lumbar spine diagnostics and treatment market estimated at $40 billion annually, contributing to overall costs of up to $134.5 billion [2][3] - Aclarion has secured its first commercial agreement with Sheridan Community Hospital in Michigan and extended its agreement with The London Clinic, increasing access to its technology [3][4] - The company has obtained private payer coverage from major UK insurers, covering 60% of private health insurance patients in greater London [3] - Aclarion's technology is supported by strong clinical data, showing an 85% improvement in patients treated based on NOCISCAN diagnostics, with ongoing clinical trials to further validate its efficacy [3][4] Industry Context - The medical devices market is experiencing significant growth, with a robust pipeline of innovations and increasing investments in research and development [1][2] - Chronic low back pain is a major health challenge affecting 266 million patients globally, highlighting the demand for effective diagnostic and treatment solutions [3]

Core Viewpoint - AmpliTech Group's AGMDC Division has relocated to the Allen Tech Hub in Allen, Texas, marking a significant step in the company's growth strategy and commitment to innovation in technology [1][2][3] Group 1: Relocation Details - The new facility at the Allen Tech Hub is designed to enhance AmpliTech's capabilities in delivering next-generation MMIC and Microwave Technology solutions for Public and Private 5G networks [2][3] - The move reflects the company's dedication to fostering innovation and providing an environment conducive to collaboration and growth [2][3] Group 2: Strategic Importance - The relocation is a testament to AmpliTech's rapid growth and the increasing demand for its innovative products and solutions, particularly in the 5G industry [3] - The new headquarters will support current initiatives and position the company to explore new opportunities and technologies [3] Group 3: Company Overview - AmpliTech Group, Inc. operates five divisions and is a leading designer, developer, manufacturer, and distributor of RF microwave components and 5G network solutions, serving global markets including telecommunications, satellite communications, and defense [4]

Company Overview - American Shared Hospital Services (ASHS) is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services [3] - The company collaborates with major global Original Equipment Manufacturers (OEMs) to provide cutting-edge clinical treatment systems and software for cancer treatment [3] - ASHS offers a range of products including MR Guided Radiation Therapy Linacs, Advanced Digital Linear Accelerators, Proton Beam Therapy Systems, and Brachytherapy systems [3] Financial Results Announcement - The company will hold a conference call to discuss its second quarter 2024 financial results on August 14, 2024, at 6:30 PM ET [1] - A press release detailing the financial results will be issued after the market closes on the same day [1] Participation Information - Domestic callers can join the call by dialing 844.413.3972, while international callers can dial 412.317.5776 [2] - A simultaneous webcast will be available on the company's website and for institutional investors [2] - A replay of the call will be accessible until August 21, 2024, through specified phone numbers and the company's website [2]

Core Viewpoint - SKYX Technologies is set to host a Corporate Update call on August 12, 2024, to present its second quarter 2024 financial results, highlighting its mission to make homes and buildings smart, safe, and advanced as the new standard [1][2]. Group 1: Corporate Update Call Details - The Corporate Update call will take place on August 12, 2024, at 4:30 PM Eastern Time [1]. - Key participants in the call include Rani Kohen (Founder and Executive Chairman), Steve Schmidt (President), Lenny Sokolow (Co-CEO), and Marc Boisseau (CFO) [1]. - Dial-in information for the call includes a U.S./Canada number (1-877-269-7751) and an international number (1-201-389-0908) [1]. Group 2: Company Overview - SKYX holds over 97 issued and pending patents in the U.S. and globally, focusing on advanced-safe-smart platform technologies [2]. - The company owns more than 60 lighting and home décor websites, targeting both retail and commercial segments [2]. - SKYX emphasizes high quality and ease of use in its products, aiming to enhance safety and lifestyle in homes and buildings [2].

Core Points - American Shared Hospital Services (AMS) has commenced patient treatments at its new Radiation Therapy Facility, A.B. Radiocirugía y Radioterapia de Puebla, in Puebla, Mexico, which is located 80 miles from Mexico City [1] - AMS has established a Joint Venture (JV) with Guadalupe Amor Y Bien, holding 85% and 15% ownership interests respectively, to provide cancer treatment services at the facility [2] - The facility is equipped with an Elekta Versa HD linear accelerator, which is an upgrade from the previous equipment, and aims to serve a population of over six million people in the region [2] - The introduction of advanced treatment modalities, including IMRT, VMAT, SBRT, and Radiosurgery, is expected to significantly enhance patient outcomes and drive demand for services [3] - The JV aims to reduce patient travel for advanced care, as previously patients had to travel to Mexico City for treatment [3][2] Company Strategy - The expansion into Mexico is part of AMS's international strategy, which also includes existing Gamma Knife centers in Peru and Ecuador [3] - The company has announced a joint venture with Hospital San Javier to treat patients with advanced Leksell Gamma Knife technology in Guadalajara, Mexico [3] - AMS's VP of Sales and Business Development-International emphasized that the ability to offer additional treatment modalities will provide a competitive advantage in the region [3] Market Context - The facility had not operated since 2020, and the reintroduction of services is seen as a critical need for the local population [2] - The upgrade to the Versa linear accelerator is expected to generate significant demand due to its advanced capabilities, allowing for single-session treatments compared to multiple sessions required by other options [3]

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggrega ...

Core Viewpoint - Oncocyte Corp. will announce its second quarter 2024 financial results on August 8, 2024, followed by a conference call and webcast to discuss the results and highlights [1]. Company Overview - Oncocyte is a diagnostics technology company focused on providing clarity and confidence to physicians and patients through its tests [1]. - The company's key products include: - VitaGraft™, a clinical blood-based solid organ transplantation monitoring test - GraftAssure™, a research use only (RUO) blood-based solid organ transplantation monitoring test - DetermaIO™, a gene expression test assessing the tumor microenvironment to predict response to immunotherapies - DetermaCNI™, a blood-based monitoring tool for therapeutic efficacy in cancer patients [1]. Conference Call Details - The conference call will take place on August 8, 2024, at 5:00 p.m. Eastern Time, with a toll-free dial-in number for participants [1]. - A live webcast will be available on the company's website, and a replay will be accessible shortly after the call concludes [1].

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules PITTSBURGH, PA, August 1, 2024 – Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”) (Nasdaq: LIPO), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,066,000 shares of common stock (or pre-funded warrants in lieu the ...

Company Overview - Phytanix Bio is a preclinical stage pharmaceutical company focused on developing therapeutics based on cannabinoid and cannabinoid-like molecules [1][15] - The company was founded by former members of GW Pharmaceuticals, leveraging their extensive experience and intellectual property to create innovative therapies for serious unmet medical needs [15] Strategic Vision and Growth Potential - The newly released investor deck outlines Phytanix Bio's strategic vision, scientific advancements, and growth potential as it progresses towards next-generation cannabinoid medicines [1][10] - The global cannabis pharmaceuticals market was estimated at USD 3.4 billion in 2023 and is projected to grow at a CAGR of 53.3% from 2024 to 2030, indicating significant market opportunities for Phytanix Bio [13] Scientific and Clinical Progress - The investor deck provides detailed updates on the company's preclinical studies, research collaborations, and upcoming clinical milestones [14] - Phytanix Bio is developing lead product candidates aimed at treating treatment-resistant facial seizures and Painful Bladder Syndrome (PBS) [14] Intellectual Property Portfolio - The company holds exclusive intellectual property related to cannabinoid and cannabinoid-like medicines, including patents and proprietary technologies [14] Management Team - The leadership team includes experienced professionals such as CEO Barrett Evans, COO Colin Stott, and Chief Legal Officer Dominic Schiller, all of whom are former key members of GW Pharmaceuticals [14] Business Combination Agreement - Phytanix Bio has entered into a Business Combination Agreement with Chain Bridge I (Nasdaq: CBRG), a blank-check company, to facilitate a merger or similar business combination [3][10]